DEPAKOTE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DEPAKOTE (DEPAKOTE).
Increases GABA levels by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase; also blocks voltage-gated sodium channels and T-type calcium channels.
| Metabolism | Extensively metabolized in the liver via glucuronidation (UGT1A3, UGT2B7), beta-oxidation, and cytochrome P450 (CYP) pathways; minor CYP involvement (CYP2C9, CYP2C19, CYP2A6). |
| Excretion | Renal: <3% as unchanged drug; >95% as metabolites (glucuronide conjugates, oxidation products). Biliary/fecal: minor, <5%. |
| Half-life | Terminal: 9-16 hours (mean 12 h); extended with hepatic dysfunction, co-administered enzyme inhibitors, or in elderly. |
| Protein binding | 90-95% bound, primarily to albumin; concentration-dependent at therapeutic levels. |
| Volume of Distribution | 0.13-0.23 L/kg; distributes mainly in plasma and extracellular fluid; minimal CNS penetration. |
| Bioavailability | Oral: ~100% (immediate-release); extended-release formulations ~90% relative to IV. |
| Onset of Action | Oral: 1-4 hours for peak serum concentrations; clinical effect in 3-5 days for seizure control; weeks for mood stabilization. IV: immediate for seizure termination. |
| Duration of Action | Oral: 8-12 hours for steady-state; therapeutic effect persists with regular dosing. IV: seizure control duration 4-6 hours post-infusion. |
| Action Class | Sodium channel modulators (AED) |
| Brand Substitutes | Divox 1000mg Tablet, Divalin OD 1000mg Tablet, StayHappi Divalproex 1000mg Tablet, Dixval OD 1000mg Tablet, Proexsun 1000mg Tablet |
Initial dose 750 mg/day PO in divided doses; increase by 250-500 mg/day every 3-7 days; maintenance dose 1000-2000 mg/day PO divided BID or TID; maximum 60 mg/kg/day.
| Dosage form | TABLET, DELAYED RELEASE |
| Renal impairment | No dose adjustment required for renal impairment; dialyzable, post-hemodialysis supplementation may be needed. |
| Liver impairment | Contraindicated in severe hepatic impairment; in mild-to-moderate (Child-Pugh A/B), reduce dose and monitor liver function; avoid in Child-Pugh C. |
| Pediatric use | 10-15 mg/kg/day PO divided BID or TID; increase by 5-10 mg/kg/day weekly; maximum 60 mg/kg/day; monitor serum levels and side effects. |
| Geriatric use | Start at lower doses, 250-500 mg/day PO; titrate slowly; monitor for encephalopathy, thrombocytopenia, and tremor; reduce dose if renal function decreased. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DEPAKOTE (DEPAKOTE).
| Breastfeeding | Valproate excreted in breast milk; M/P ratio ~0.05–0.10. Infant serum levels <10% maternal therapeutic levels. Considered compatible with breastfeeding by some sources, but monitor infant for sedation, thrombocytopenia, hepatic dysfunction. Benefits of breastfeeding generally outweigh low risk, especially if maternal valproate dose ≤1000 mg/day. |
| Teratogenic Risk | First trimester: High risk of neural tube defects (spina bifida, anencephaly) with incidence ~1.5–2.9% for monotherapy; increased risk of orofacial clefts, cardiovascular defects, hypospadias. Second/third trimester: Risk of neurodevelopmental delay, autism spectrum disorder, reduced IQ; may cause fetal growth restriction, preterm birth. Peripartum: Neonatal hemorrhage, hepatic toxicity, hypoglycemia, withdrawal symptoms. |
■ FDA Black Box Warning
Hepatotoxicity, especially in children under 2 years, patients with metabolic disorders, or those on multiple anticonvulsants; Fetal risk, including neural tube defects (spina bifida) and other congenital malformations; Pancreatitis, including fatal hemorrhagic cases.
| Serious Effects |
Hypersensitivity to valproate derivatives, hepatic disease or significant hepatic dysfunction, known mitochondrial disorders caused by POLG mutations, suspected mitochondrial disease in children under 2 years, and known urea cycle disorders.
| Precautions | Hepatotoxicity (monitor LFTs), pancreatitis (discontinue if symptoms), thrombocytopenia, hyperammonemic encephalopathy, teratogenicity, multiorgan hypersensitivity reactions, sedation, and weight gain. |
Loading safety data…
| Fetal Monitoring | Preconception: folate 5 mg/day; ensure lowest effective dose. First trimester: high-resolution ultrasound for neural tube defects (NTD) at 16-18 weeks, fetal echocardiography at 18-22 weeks. Throughout: serial growth scans, amniocentesis for NTD if indicated. Maternal: liver function tests, CBC, coagulation profile, valproate serum concentrations (target lowest effective level). Newborn: monitoring for hemorrhage (vitamin K prophylaxis), hypoglycemia, withdrawal. |
| Fertility Effects | May cause reversible ovulatory dysfunction due to weight gain, insulin resistance, polycystic ovary syndrome (PCOS) in some women; reported increased risk of anovulation. No direct adverse effect on spermatogenesis reported. Valproate does not impair fertility after discontinuation. |